SB 465Session 2026
classifying xylazine as a schedule III controlled drug.
Progress
- Introduced
- In committee
- Passed Senate
- Passed legislature Not yet
- Sent to governor Not yet
- Became law Not yet
Legislative history
-
House
Inexpedient to Legislate: MA VV 04/23/2026 HJ 11 P. 55
-
House
Minority Committee Report: Ought to Pass
-
House
Majority Committee Report: Inexpedient to Legislate 04/14/2026 (Vote 11-5; RC)
-
House
Executive Session: 04/14/2026 01:00 pm GP 153
-
House
Full Committee Work Session: 04/07/2026 01:00 pm GP 153
-
House
Public Hearing: 03/31/2026 01:30 pm GP 153
-
House
Introduced (in recess of) 03/12/2026 and referred to Environment and Agriculture HJ 8 P. 114
-
Senate
Ought to Pass with Amendment #2026-0842s, MA, VV; OT3rdg; 03/05/2026; SJ 5
-
Senate
Committee Amendment # 2026-0842s, AA, VV; 03/05/2026; SJ 5
-
Senate
Committee Report: Ought to Pass with Amendment # 2026-0842s, 03/05/2026; Vote 5-0; CC; SC 8
-
Senate
Hearing: 02/10/2026, Room 100, SH, 01:30 pm; SC 5A
-
Senate
Introduced 01/07/2026 and Referred to Judiciary; SJ 1